ScFv based Bispecific Antibody (BsAb) Fragment Generation Service

Accelerate Your Research and Development!

Are you currently facing challenges in antibody development, difficulty in protein expression and purification, or long drug development cycles for complex bispecifics? Creative Biolabs' scFv based BsAb Fragments (scFv-CH1/CL, scFv-CH3, Miniantibody) Generation Service helps you accelerate drug discovery and develop highly specific antibodies through innovative protein engineering techniques and advanced recombinant DNA technology.

Contact our team to get an inquiry now!

scFv based BsAb Fragments

The Single-Chain Variable Fragment (scFv) is a compact fusion protein, uniting an antibody's V_H (Heavy Chain Variable) and V_L (Light Chain Variable) domains via a short, synthetic peptide linker. This bridge is specifically engineered to be rich in glycine and serine/threonine to ensure maximum flexibility and enhanced solubility, allowing the domains to fold correctly and retain full antigen-binding function. As the core building block for bispecific antibodies (bsAbs), the scFv format is highly valued for its inherently small size and superior tissue penetration, enabling rapid access to solid tumor microenvironments. Creative Biolabs' service directly addresses these key limitations through rational engineering and linker optimization, maximizing the therapeutic potential of these complex molecules.

Fig.1 Forms of ScFv fragments BsAbs.

scFv-CH1/CL

This arrangement involves two distinct scFv modules, each targeting a specific antigen. These modules are covalently fused to the constant domains CH1 and CL (scFvA-CH1 and scFvB-CL). The resulting heterodimeric structure is stabilized by the natural dimerization tendency of the CH1/CL domains, further secured by a native inter-chain disulfide bridge. This construct maintains a 1+1 binding stoichiometry and an approximate molecular mass of 75 kDa. Its relatively small size leads to accelerated systemic clearance from circulation, a crucial factor for applications where fast elimination is desired.

scFv-CH3

The scFv-CH3 construct utilizes the CH3 segments of an IgG constant domain as a dimerization scaffold. The final molecule requires co-expression of two chains scFvA-CH3 and scFvB-CH3) to form an asymmetric, bivalent entity. Controlled heterodimerization is achieved through purposeful amino acid substitutions within the CH3 interface, leveraging established methods like 'knobs-into-holes' or optimized charge pairs. The strategic inclusion of the CH3 domains is paramount, as it grants enhanced serum persistence and a prolonged half-life when compared to simple variable domain fragments.

Miniantibody

Defined as a dimeric antibody fragment, the Miniantibody is composed of two scFv units, each capable of unique antigen recognition (1+1 binding stoichiometry). The scFv components are connected by an intervening, flexible hinge region. Dimerization is mediated by intra-chain disulfide linkages specifically engineered into this hinge structure. With a molecular weight of roughly 50 kDa, this format's highly reduced scale provides superior penetration into solid tissues, making it highly valuable for targeted therapeutic research and clinical diagnostic imaging applications.

Why Choose Us?

Creative Biolabs' scFv based BsAb Fragments Generation Service is built on the expertise required to manage the unique, non-standard challenges of fragment engineering, ensuring your therapeutic leads are robust and commercially viable. Our systematic approach to controlling multimerization, enhancing stability, and optimizing non-traditional purification sets us apart.

Key Advantages & Unique Features:

• Precision Linker Engineering for Avidity Control: We move beyond standard linker selection by actively using specific linker lengths and flexible chemistries to enforce the required valency. For T-cell engagers, our expertise forces dimerization into the high-avidity diabody format, directly boosting functional potency (Published Data on dissociation constants shows up to 40-fold lower KD).
• Decoupling PK and Stability: We generate the most stable core fragment possible, which is the necessary first step before any half-life extension. This foundational stability ensures that subsequent fusion to an Fc domain or albumin-binding protein does not compromise the molecular integrity.
• Scalable Non-Fc Purification: We are experts in developing robust purification pathways suitable for high-throughput bacterial systems. Our validated use of optimized non-Fc tags (e.g., Histidine or Protein L) solves the manufacturing bottleneck posed by the lack of a Protein A/G binding site.
• Rational Toxicity Mitigation: In complex targeting scenarios, such as overcoming the Antigen Sink Toxicity challenge of targets like CD47, we apply affinity tuning to precisely design a low-affinity arm and a high-affinity arm, minimizing systemic exposure while retaining localized tumor efficacy.

Experience the Creative Biolabs Advantage - Get a Quote Today

FAQs